Study: On­col­o­gists who take phar­ma mon­ey are more like­ly to pro­vide low-val­ue treat­ments

On­col­o­gists were more like­ly to pro­vide low-val­ue can­cer drugs to their pa­tients af­ter re­ceiv­ing per­son­al pay­ments from phar­ma com­pa­nies than those who did not re­ceive such pay­ments, ac­cord­ing to a study pub­lished Wednes­day in the BMJ.

The re­searchers, led by Aaron Mitchell, an on­col­o­gist at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter in New York City, iden­ti­fied sev­er­al can­cer treat­ments that were found to not help pa­tients, in­clud­ing prici­er drugs that aren’t bet­ter than al­ter­na­tives, and treat­ments that don’t im­prove out­comes but can cause se­ri­ous side ef­fects. Us­ing CMS’ Open Pay­ments data­base, the team found that on­col­o­gists who had re­ceived per­son­al pay­ments, like free meals and speak­ing or con­sult­ing fees, were more like­ly to pre­scribe those low-val­ue drugs to pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER